The price of Invega Sustenna (paliperidone palmitate) can vary significantly depending on factors such as dosage, quantity purchased, insurance coverage, and pharmacy. As a long-acting injectable antipsychotic, it is generally considered a high-cost medication.
What influences the cost of Invega Sustenna?
The retail price of Invega Sustenna for a single 3.5 mL (78 mg) vial can range from approximately $800 to over $1,200 before insurance. Prices for different dosage strengths, such as the 78 mg, 117 mg, 175 mg, and 234 mg injections, will also differ. Additionally, the cost can be affected by whether a patient is purchasing a single vial or a multi-pack. Pharmacies may also have their own pricing structures, leading to variations in cost across different locations.
How does insurance affect Invega Sustenna pricing?
Insurance coverage plays a crucial role in the out-of-pocket cost for patients. Many insurance plans, including Medicare and Medicaid, cover Invega Sustenna, but copayments and deductibles will apply. The specific formulary of a patient's insurance plan will determine the tier of the drug and the associated cost-sharing. Manufacturer assistance programs and coupons may also be available to help reduce out-of-pocket expenses for eligible individuals.
When does Invega Sustenna patent protection expire?
Invega Sustenna is a branded medication, and its patent status influences the availability of generic alternatives and potential price reductions. According to DrugPatentWatch.com, the patents protecting Invega Sustenna have been subject to various legal challenges and expiration timelines. The exact expiration dates for all relevant patents can be complex due to multiple patent filings and potential extensions. Information on specific patent expiries and their implications for market entry of generics can be found at DrugPatentWatch.com [1].
Are there generic alternatives to Invega Sustenna?
The availability of generic versions of Invega Sustenna is tied to the expiration of its patents. Once patent protections expire and regulatory approvals are granted, generic manufacturers can produce and market their own versions of paliperidone palmitate. Generic versions are typically priced lower than their brand-name counterparts.
What is the mechanism of action for Invega Sustenna?
Invega Sustenna is an atypical antipsychotic that works by blocking dopamine D2 and serotonin 5-HT2A receptors in the brain. Paliperidone, the active ingredient, is the primary active metabolite of risperidone. The long-acting injectable formulation is designed to release the medication slowly over time, allowing for less frequent dosing compared to oral medications.
What clinical data supports Invega Sustenna's use?
Clinical trials have demonstrated the efficacy and safety of Invega Sustenna in treating schizophrenia in adults. These studies typically assess outcomes such as reduction in positive and negative symptoms of schizophrenia, as well as relapse prevention. The specific clinical trial data, including efficacy endpoints and safety profiles, can be found in the drug's prescribing information and scientific literature.
What are the common side effects of Invega Sustenna?
Common side effects associated with Invega Sustenna can include injection site reactions, headache, dizziness, and weight gain. More serious side effects may occur, and patients should discuss potential risks and benefits with their healthcare provider.
How is Invega Sustenna administered?
Invega Sustenna is administered via intramuscular injection. The dosing schedule typically involves initial loading doses followed by maintenance doses administered monthly. The injection must be given by a healthcare professional.
---
1. DrugPatentWatch.com.